AbbVie Inc. ABBV reported adjusted earnings of $3.00 per share for the third quarter of 2024, beating the Zacks Consensus Estimate of $2.92. The reported earnings also exceeded the company’s ...

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. As with other drugs, Elahere can cause side effects, such as eye problems, nerve ...

AbbVie Inc. ABBV reported adjusted earnings of $3.00 per share for the third quarter of 2024, beating the Zacks Consensus ...

We are also seeing nice sequential revenue growth from Elahere and Epkinly ... Based upon the relatively higher price point of filler procedures in a still challenging U.S. economic environment ...

Unlike many other e-readers, the Boox Palma runs on Android 11 and comes with the Google Play Store built-in, so you can read ...

CHICAGO — A real-world study of the ocular side effects of the gynecological cancer treatment mirvetuximab (Elahere) has found more than two of three women taking the drug experienced some type ...

The biotech chose to add a second candidate in April when it inked a $1.8 billion deal to buy ProfoundBio for a rival to AbbVie’s Elahere. It had a third asset thrust into its hands in August ...

Inc. The intangible asset impairment was triggered by selection of Imbruvica for price negotiation as part of the IRA of 2022, which contributed to a significant decrease in the estimated future cash ...

Global Elahere net revenues were $139 million. Global net revenues from the neuroscience portfolio were $2.363 billion, an increase of 15.6 percent on a reported basis, or 16.0 percent on an ...